Life Sciences Research Partners

Life Sciences Research Partners

Life Sciences Research Partners is an investment firm focused on the life sciences sector, with a particular emphasis on early-stage therapeutics and diagnostics. Its founding team and wealth origin are not publicly documented, which limits visibility into its governance structure. The firm targets investments in companies developing novel drug discovery platforms, precision medicine tools, and digital health technologies. It typically leads or co-leads seed and Series A rounds, taking board seats and providing operational support to portfolio companies. Publicly named investments include a role in the 2018 $55M Series C for Harpoon Therapeutics (per SEC filing, 2018). The firm also backed Seer, a proteomics company that went public in 2020 (per S-1 filing, 2020). Geographically, it balances US and European deal flow, with a concentration in the Boston-Cambridge corridor and the Belgian biotech cluster anchored by KU Leuven. The firm's total assets under management are not publicly disclosed. Its professional headcount is unknown, and it does not operate any publicly identifiable adjacent vehicles such as a companion venture fund or philanthropic foundation. No recent operational event — such as a new fund close or leadership change — is available from public sources for the past 24 months. LSRP's structural differentiator is its transatlantic platform, rare among early-stage life sciences venture investors. The ability to originate in both the US and European innovation hubs — and to support portfolio companies with regulatory and clinical expertise across both markets — is a distinguishing operational feature. The firm's governance and succession plans remain opaque.